Table 3.
Correlations between Clinicopathological Features and DNA Damage Response proteins in Sporadic Gastric Cancer
| BRCA1 | BRCA2 | MRE11 | Rad51C | γH2AX | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Negative | Positive | p | Negative | Positive | p | Negative | Positive | p | Negative | Positive | p | Negative | Positive | p | ||
| Gender | Male | 70 (68) | 142 (79.3) | 0.033 | 90 (70.3) | 153 (77.7) | 0.136 | 85 (72.6) | 163 (75.8) | 0.526 | 111 (75) | 129 (74.1) | 0.86 | 130 (71.4) | 81 (79.4) | 0.14 |
| Female | 33 (32) | 37 (20.7) | 38 (29.7) | 44 (22.3) | 32 (27.4) | 52 (24.2) | 37 (25) | 45 (25.9) | 52 (28.6) | 21 (20.6) | ||||||
| Differentiation | Well differentiated | 2 (1.9) | 28 (15.6) | < 0.001 | 8 (6.3) | 22 (11.2) | < 0.001 | 7 (6) | 24 (11.2) | 0.116 | 13 (8.8) | 18 (10.3) | < 0.001 | 10 (5.5) | 16 (15.7) | 0.001 |
| Moderately differentiated | 37 (35.9) | 77 (43) | 39 (30.5) | 97 (49.2) | 44 (37.6) | 92 (42.8) | 43 (29.1) | 88 (50.6) | 71 (39) | 50 (49) | ||||||
| Poorly differentiated | 64 (62.1) | 74 (41.3) | 81 (63.3) | 78 (39.6) | 66 (56.4) | 99 (46) | 92 (62.2) | 68 (39.1) | 101 (55.5) | 36 (35.3) | ||||||
| Lauren classification | Intestinal | 37 (35.9) | 96 (53.6) | 0.016 | 36 (28.1) | 117 (59.4) | < 0.001 | 52 (44.4) | 102 (47.4) | 0.734 | 44 (29.7) | 104 (59.8) | < 0.001 | 77 (42.3) | 56 (54.9) | 0.008 |
| Diffuse | 46 (44.7) | 56 (31.3) | 66 (51.6) | 52 (26.4) | 47 (40.2) | 77 (35.8) | 74 (50) | 45 (25.9) | 78 (42.9) | 25 (24.5) | ||||||
| Mixed | 20 (19.4) | 27 (15.1) | 26 (20.3) | 28 (14.2) | 18 (15.4) | 36 (16.7) | 30 (20.3) | 25 (14.4) | 27 (14.8) | 21 (20.6) | ||||||
| T stage | T1 | 20 (19.4) | 72 (40.2) | 0.001 | 58 (45.3) | 52 (26.4) | 0.003 | 26 (22.2) | 87 (40.5) | 0.003 | 60 (40.5) | 48 (27.6) | 0.008 | 40 (22) | 47 (46.1) | < 0.001 |
| T2 | 64 (62.1) | 89 (49.7) | 55 (43) | 119 (60.4) | 78 (66.7) | 100 (46.5) | 65 (43.9) | 106 (60.9) | 109 (59.9) | 49 (48) | ||||||
| T3 | 19 (18.4) | 16 (8.9) | 15 (11.7) | 24 (12.2) | 13 (11.1) | 26 (12.1) | 23 (15.5) | 18 (10.3) | 33 (18.1) | 4 (3.9) | ||||||
| T4 | 0 (0) | 2 (1.1) | 0 (0) | 2 (1) | 0 (0) | 2 (0.9) | 0 (0) | 2 (1.1) | 0 (0) | 2 (2) | ||||||
| LN metastasis | Absent | 39 (37.9) | 102 (57) | 0.002 | 75 (58.6) | 92 (46.7) | 0.036 | 50 (42.7) | 123 (57.2) | 0.012 | 78 (52.7) | 89 (51.1) | 0.781 | 77 (42.3) | 64 (62.7) | 0.001 |
| Present | 64 (62.1) | 77 (43) | 53 (41.4) | 105 (53.3) | 67 (57.3) | 92 (42.8) | 70 (47.3) | 85 (48.9) | 105 (57.7) | 38 (37.3) | ||||||
| TNM stage | I | 42 (40.8) | 108 (60.3) | 0.002 | 80 (62.5) | 97 (49.2) | 0.062 | 54 (46.2) | 128 (59.5) | 0.064 | 84 (56.8) | 92 (52.9) | 0.526 | 81 (44.5) | 67 (65.7) | 0 |
| II | 23 (22.3) | 37 (20.7) | 24 (18.8) | 48 (24.4) | 32 (27.4) | 43 (20) | 28 (18.9) | 42 (24.1) | 40 (22) | 24 (23.5) | ||||||
| III | 38 (36.9) | 34 (19) | 24 (18.8) | 52 (26.4) | 31 (26.5) | 44 (20.5) | 36 (24.3) | 40 (23) | 61 (33.5) | 11 (10.8) | ||||||